Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.87 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.87 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.87 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.87 |
| ▸ | CHRNA6 | Q15825 | 3/20 | 0.87 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | GABRP | O00591 | 1/20 | 0.50 |
| ▸ | GABRD | O14764 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.50 |
| ▸ | GABRE | P78334 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5455311 | 0.98 | CHRNB2 (0.83) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL27109077 | 0.96 | CHRNB2 (0.80) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL27109069 | 0.93 | CHRNB2 (0.75) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL8314 | 0.93 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1706129 | 0.92 | CHRNB2 (0.74) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL1018088 | 0.91 | CHRNB2 (0.95) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Piperazine SCHEMBL28221523 | 0.91 | CHRNB2 (0.95) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL493736 | 0.89 | CHRNB2 (0.69) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL911091 | 0.89 | CHRNB2 (0.83) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1284051 | 0.89 | CHRNB2 (0.69) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | claimed |
| EP-1301480-B1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2007-09-12 | — | — | EP | claimed |
| US-20250179066-A1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | PRAZER THERAPEUTICS INC. (KR) | 2024-12-26 | — | — | US | disclosed |
| WO-2024112119-A1 | DEGRADER FOR DECOMPOSING CMET PROTEIN, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 이노큐어테라퓨틱스 | 2024-05-30 | — | — | WO | disclosed |
| EP-4288424-A1 | NOVEL HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-12-13 | — | — | EP | disclosed |
| US-20230295123-A1 | NOVEL IMIDAZOLE-PYRAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230234939-A1 | IMIDAZOLE-PYRAZOLE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN-LA ROCHE INC. (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2023285497-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022167631-A1 | NOVEL HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-08-11 | — | — | WO | disclosed |
| WO-2022074459-A2 | AUTOTAXIN INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-14 | — | — | WO | disclosed |
| US-8288389-B2 | Piperazine derivative having affinity for the histamine H3 receptor | GLAXO GROUP LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| EP-2195307-B1 | PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2012-04-18 | — | — | EP | disclosed |
| US-20100204242-A1 | Piperazine Derivative Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2010-08-12 | — | — | US | disclosed |
| EP-2195307-A1 | PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | Glaxo Group Limited (GB) | 2010-06-16 | — | — | EP | disclosed |
| WO-2010044885-A2 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20090170869-A1 | PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | US | disclosed |
| WO-2009030716-A1 | PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | WO | disclosed |
| CN-1809553-A | Piperazine derivatives and their use in the treatment of neurological and psychiatric disorders | GLAXO GROUP LTD (GB) | 2006-07-26 | — | — | CN | disclosed |
| CN-1228087-A | Substituted pyrimidine derivatives and their pharmaceutical use | ZENECA LTD (GB) | 1999-09-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179066-A1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | MRPL21, WIZ, CFTR | CHRNB2 4750/4885CHRNA3 2948/4885CHRNA4 4665/4885 |
| US-20240425517-A1 | NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION | ADRM1, SUMO1, SUMO2 | CHRNB2 4203/4885CHRNA3 4659/4885CHRNA4 4684/4885 |
| US-20230295123-A1 | NOVEL IMIDAZOLE-PYRAZOLE DERIVATIVES | CYP3A7, NISCH, ARG1 | CHRNB2 4845/4885CHRNA3 4532/4885CHRNA4 4764/4885 |
| US-20090170869-A1 | PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | CHRNB2 199/4885CHRNA3 69/4885CHRNA4 42/4885 |
| US-20100204242-A1 | Piperazine Derivative Having Affinity for the Histamine H3 Receptor | HRH3, HRH4, HRH1 | CHRNB2 199/4885CHRNA3 69/4885CHRNA4 42/4885 |
| US-20230234939-A1 | IMIDAZOLE-PYRAZOLE DERIVATIVES AS ANTIBACTERIALS | CYP3A7, NISCH, ARG1 | CHRNB2 4870/4885CHRNA3 4724/4885CHRNA4 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.